Clinical Trial

Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 9, 2025 (before its estimated January 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
To describe the immunogenicity and safety of two dosages of Sinovac rabies vaccine, as well as compared the differences with the marked WHO PQ rabies vaccine Verorab® in a post-exposure prophylaxis (PEP) schedule.
Trial Details
NCT Number NCT07055880
Lead Sponsor Sinovac Biotech Co., Ltd
Conditions Rabies
Enrollment 120 participants
Start Date 2025-07-28
Primary Completion 2026-01-15 (estimated)
Study Completion 2026-01-15 (estimated)
Updated on ClinicalTrials.gov 2025-07-09